EMA faces yet another transparency-related inquiry
This article was originally published in SRA
Executive Summary
The EU Ombudsman has launched yet another investigation into the European Medicines Agency for not supporting the tenets of transparency and turning down a request from a member of the public - in this case a journalist from the New York Times - to have full access to two of its databases1,2.